Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson And Tianjin Cancer Hospital To Conduct Joint Drug Research

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson and Cancer Hospital of Tianjin Medical University have signed an MOU to jointly develop oncology drugs. Both parties are also discussing the possibility of setting up an oncology R&D collaboration center in Tianjin's Binhai Hi-tech Industrial Park. Cancer Hospital is one of China's largest tumor prevention and treatment bases, housing an advanced tissue bank for tumor specimens. With its strong clinical techniques and resources, the hospital will make an ideal partner for Johnson & Johnson, which seeks to build up a cancer drug R&D base in Asia Pacific. Areas of cooperation will cover animal model studies, local and global clinical trials, technology and knowledge transfer, as well as training for clinicians and researchers. (Click here for more - Chinese language)

You may also be interested in...

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts